Person:
BİLGİN, HÜSEYİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

BİLGİN

First Name

HÜSEYİN

Name

Filters

2021 - 20223
Reset filters

Settings

Author: BİLGİN, HÜSEYİN × Subject: COVID-19 ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Transmission of SARS-CoV-2 in Different Districts of a County in Istanbul, March to September 2020
    (SAGE PUBLICATIONS INC, 2021-07) TOPUZOĞLU, AHMET; Bilgin, Huseyin; Topuzoglu, Ahmet; Korten, Volkan
    Epidemics caused by airborne viruses in cities with large populations create a big problem as in the current COVID-19 pandemic. Cramped lifestyle, busy workplaces, crowded public transportation, and higher household member counts are responsible for the transmission of the disease. In Turkey, Istanbul has taken the lead in the number of cases since the beginning of the epidemic. The excess population density is the major cause for disease transmission. It is essential to monitor the contaminated regions with geographical information systems on city maps. Outbreak maps visualize and help analyze the patterns of transmission and serve as a communication and education tool. A dynamic heat map video of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) polymerase chain reaction positive cases in a county of Istanbul was generated. The heat map visualizes how the epidemic spread to all the districts and the cumulative cases increased in one county of Istanbul with real attack rates.
  • No Thumbnail Available
    PublicationMetadata only
    The association of free testosterone levels with coronavirus disease 2019
    (2022) ILGIN, CAN; Apaydin, Tugce; Sahin, Bahadır; Dashdamirova, Saida; Dincer Yazan, Ceyda; Elbasan, Onur; Ilgin, Can; Bilgin, Hüseyin; Cam, Haydar Kamil; Bahramzada, Gunel; Kucuk, Aleyna; Haklar, Goncagul; Iliksu Gozu, Hulya
  • No Thumbnail Available
    PublicationMetadata only
    Association of renin angiotensin aldosterone system inhibitors and outcomes of hospitalized patients with COVID-19
    (2022-10-01) SİLİ, ULUHAN; BİLGİN, HÜSEYİN; Gupta N., Brown B. R. , Baram M., Perkins N. E. , Kaufman M., Melamed R. R. , Christie A. B. , Danesh V. C. , Denson J. L. , Cheruku S. R. , et al.
    Copyright © 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.OBJECTIVES: To determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19. DESIGN: Retrospective observational study. SETTING: Multicenter, international COVID-19 registry. SUBJECTS: Adult hospitalized COVID-19 patients on antihypertensive agents (AHAs) prior to admission, admitted from March 31, 2020, to March 10, 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Data were compared between three groups: patients on RAASIs only, other AHAs only, and those on both medications. Multivariable logistic and linear regressions were performed after controlling for prehospitalization characteristics to estimate the effect of RAASIs on mortality and other outcomes during hospitalization. Of 26,652 patients, 7,975 patients were on AHAs prior to hospitalization. Of these, 1,542 patients (19.3%) were on RAASIs only, 3,765 patients (47.2%) were on other AHAs only, and 2,668 (33.5%) patients were on both medications. Compared with those taking other AHAs only, patients on RAASIs only were younger (mean age 63.3 vs 66.9 yr; p < 0.0001), more often male (58.2% vs 52.4%; p = 0.0001) and more often White (55.1% vs 47.2%; p < 0.0001). After adjusting for age, gender, race, location, and comorbidities, patients on combination of RAASIs and other AHAs had higher in-hospital mortality than those on RAASIs only (odds ratio [OR] = 1.28; 95% CI [1.19-1.38]; p < 0.0001) and higher mortality than those on other AHAs only (OR = 1.09; 95% CI [1.03-1.15]; p = 0.0017). Patients on RAASIs only had lower mortality than those on other AHAs only (OR = 0.87; 95% CI [0.81-0.94]; p = 0.0003). Patients on ACEIs only had higher mortality compared with those on ARBs only (OR = 1.37; 95% CI [1.20-1.56]; p < 0.0001). CONCLUSIONS: Among patients hospitalized for COVID-19 who were taking AHAs, prior use of a combination of RAASIs and other AHAs was associated with higher in-hospital mortality than the use of RAASIs alone. When compared with ARBs, ACEIs were associated with signifcantly higher mortality in hospitalized COVID-19 patients.